3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
11
Gastrointestinal
2
Gynecologic
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Emergence Delirium
1
Delirium
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
26
Magnetic Resonance Spectroscopy
14
Nivolumab
13
Docetaxel
13
Specimen Handling
11
Radiotherapy
9
Paclitaxel
9
Radiosurgery
8
Early Intervention, Educational
8
Cyclophosphamide
8
Gemcitabine
7
atezolizumab
6
Taxes
6
Surveys and Questionnaires
6
Standard of Care
6
Psychiatric Rehabilitation
6
Ipilimumab
6
Carboplatin
6
sargramostim
5
Pemetrexed
5
Methods
5
motexafin gadolinium
4
fludarabine
4
X-Rays
4
Interviews as Topic
4
Immunoglobulin G
4
Fluorouracil
4
Educational Status
4
Cisplatin
4
Biopsy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Propofol
×
Genitourinary
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled